{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:07:34Z","timestamp":1769155654691,"version":"3.49.0"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cystic fibrosis (CF) pulmonary exacerbations (PEx) are clinical events that commonly result in increased treatment burden, decreased quality of life, and accelerated lung disease progression. CF PEx have historically been approached as though dealing with acute infections, and antibiotic treatments have been associated with improved outcomes. In this review, we discuss data supporting a causal role of CF airway infection in PEx as well studies that highlight our knowledge gaps in regard to PEx definitions, pathophysiology, and optimal treatment approaches. In the era of highly effective cystic fibrosis transmembrane conductance regulator modulator therapy, and the continually increasing health and longevity of persons with CF, a better understanding of PEx and further optimization of PEx antibiotic treatment approaches are needed.<\/jats:p>","DOI":"10.1093\/jpids\/piac062","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T16:01:14Z","timestamp":1662566474000},"page":"S40-S45","source":"Crossref","is-referenced-by-count":8,"title":["The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-0867","authenticated-orcid":false,"given":"Lindsay J","family":"Caverly","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Michigan Medical School , Ann Arbor, Michigan , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald R","family":"VanDevanter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Case Western Reserve University School of Medicine , Cleveland, Ohio , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"2022090715560877700_CIT0001","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet (London, England)"},{"key":"2022090715560877700_CIT0002","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ppul.25248","article-title":"Epidemiologic Study of Cystic Fibrosis: 25 years of observational research","volume":"56","author":"Konstan","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0003","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jcf.2015.10.006","article-title":"IV-treated pulmonary exacerbations in the prior year: an important independent risk factor for future pulmonary exacerbation in cystic fibrosis","volume":"15","author":"VanDevanter","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0004","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1164\/rccm.201610-2172OC","article-title":"Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations. eICE study results","volume":"196","author":"Lechtzin","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090715560877700_CIT0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.121.1.64","article-title":"Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis","volume":"121","author":"Britto","year":"2002","journal-title":"Chest"},{"key":"2022090715560877700_CIT0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2007.03.006","article-title":"Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis","volume":"151","author":"Konstan","year":"2007","journal-title":"J Pediatr"},{"key":"2022090715560877700_CIT0007","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ppul.21311","article-title":"Pulmonary outcome prediction (POP) tools for cystic fibrosis patients","volume":"45","author":"Van Devanter","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0008","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"key":"2022090715560877700_CIT0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1164\/rccm.200405-667OC","article-title":"One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis","volume":"171","author":"Ellaffi","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090715560877700_CIT0011","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ppul.22652","article-title":"Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis","volume":"48","author":"Wagener","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0012","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2012.5214","article-title":"Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial","volume":"307","author":"Rosenfeld","year":"2012","journal-title":"JAMA"},{"key":"2022090715560877700_CIT0013","volume-title":"Cystic Fibrosis Foundation Patient Registry","author":"Cystic Fibrosis Foundation","year":"2019"},{"key":"2022090715560877700_CIT0014","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090715560877700_CIT0015","first-page":"**","article-title":"Opportunistic pathogens in CF","volume":"**","author":"Blanchard","year":"2022","journal-title":"J Pediatr Infect Dis"},{"key":"2022090715560877700_CIT0016","first-page":"**","article-title":"Current treatment paradigms for airway infection in CF","volume":"**","author":"Somayaji","year":"2022","journal-title":"J Pediatr Infect Dis"},{"key":"2022090715560877700_CIT0017","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz364","article-title":"Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections","author":"Waters","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022090715560877700_CIT0018","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0019","first-page":"**","article-title":"Antimicrobial susceptibility testing in CF","volume":"**","author":"LiPuma","year":"2022","journal-title":"J Pediatr Infect Dis"},{"key":"2022090715560877700_CIT0020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jcf.2016.04.005","article-title":"Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis","volume":"15","author":"VanDevanter","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0021","first-page":"289","article-title":"Survival of patients with cystic fibrosis","volume":"120","author":"Huang","year":"1970","journal-title":"Am J Dis Child"},{"key":"2022090715560877700_CIT0022","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1136\/adc.47.256.908","article-title":"Bacterial infection in cystic fibrosis","volume":"47","author":"Robert May","year":"1972","journal-title":"Arch Dis Child"},{"key":"2022090715560877700_CIT0023","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1651-2227.1983.tb09789.x","article-title":"Frequent antibiotics therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection","volume":"72","author":"Szaff","year":"1983","journal-title":"Acta P\u00e6diatrica"},{"key":"2022090715560877700_CIT0024","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1651-2227.1987.tb17271.x","article-title":"Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients","volume":"76","author":"Pedersen","year":"1987","journal-title":"Acta Paediatr Scand"},{"key":"2022090715560877700_CIT0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"2022090715560877700_CIT0026","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0027","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2022090715560877700_CIT0028","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/archpedi.1980.02130240018007","article-title":"Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy","volume":"134","author":"Wientzen","year":"1980","journal-title":"Am J Dis Child"},{"key":"2022090715560877700_CIT0029","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-3476(87)80217-2","article-title":"Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis","volume":"111","author":"Gold","year":"1987","journal-title":"J Pediatr"},{"key":"2022090715560877700_CIT0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/ajrccm\/141.4_Pt_1.914","article-title":"Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone","volume":"141","author":"Regelmann","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"2022090715560877700_CIT0031","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/thorax.55.5.355","article-title":"Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs","volume":"55","author":"Elborn","year":"2000","journal-title":"Thorax"},{"key":"2022090715560877700_CIT0032","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jcf.2012.11.011","article-title":"Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005","volume":"12","author":"VanDevanter","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0033","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1378\/chest.15-0676","article-title":"Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis","volume":"149","author":"Salsgiver","year":"2016","journal-title":"Chest"},{"key":"2022090715560877700_CIT0034","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.123.1.20","article-title":"Factors influencing outcomes in cystic fibrosis: a center-based analysis","volume":"123","author":"Johnson","year":"2003","journal-title":"Chest"},{"key":"2022090715560877700_CIT0035","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0036","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcf.2016.01.005","article-title":"Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"15","author":"Elborn","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0037","doi-asserted-by":"crossref","first-page":"e1097981","DOI":"10.1371\/journal.pone.0109798","article-title":"The microbial community of the cystic fibrosis airway is disrupted in early life","volume":"9","author":"Renwick","year":"2014","journal-title":"PLoS One"},{"key":"2022090715560877700_CIT0038","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ppul.20097","article-title":"Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease","volume":"38","author":"Murphy","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0039","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"key":"2022090715560877700_CIT0040","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/civ377","article-title":"Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis","volume":"61","author":"Mayer-Hamblett","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022090715560877700_CIT0041","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1513\/AnnalsATS.201309-310OC","article-title":"Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis","volume":"11","author":"Martiniano","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2022090715560877700_CIT0042","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/ppul.21442","article-title":"Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers","volume":"46","author":"Kraynack","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0043","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090715560877700_CIT0044","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/ppul.24577","article-title":"Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis","volume":"55","author":"Wagener","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0045","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1513\/AnnalsATS.201903-270OC","article-title":"Measures of cystic fibrosis airway microbiota during periods of clinical stability","volume":"16","author":"Caverly","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2022090715560877700_CIT0046","doi-asserted-by":"crossref","first-page":"e45001","DOI":"10.1371\/journal.pone.0045001","article-title":"The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations","volume":"7","author":"Fodor","year":"2012","journal-title":"PLoS One"},{"key":"2022090715560877700_CIT0047","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2049-2618-1-27","article-title":"Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation","volume":"1","author":"Price","year":"2013","journal-title":"Microbiome"},{"key":"2022090715560877700_CIT0048","article-title":"Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention","author":"Cuthbertson","year":"2015","journal-title":"ISME J"},{"key":"2022090715560877700_CIT0049","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1128\/JCM.42.11.5176-5183.2004","article-title":"Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling","volume":"42","author":"Rogers","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2022090715560877700_CIT0050","first-page":"**","article-title":"The airway microbiome in CF","volume":"**","author":"Parkins","year":"2022","journal-title":"J Pediatr Infect Dis"},{"key":"2022090715560877700_CIT0051","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2019-214187","article-title":"Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome","author":"Nelson","year":"2020","journal-title":"Thorax"},{"key":"2022090715560877700_CIT0052","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/thoraxjnl-2019-214191","article-title":"Sputum microbiota in adults with CF associates with response to inhaled tobramycin","volume":"75","author":"Heirali","year":"2020","journal-title":"Thorax"},{"key":"2022090715560877700_CIT0053","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcf.2019.02.010","article-title":"The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome","volume":"18","author":"Heirali","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0054","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40168-017-0265-7","article-title":"The effects of inhaled aztreonam on the cystic fibrosis lung microbiome","volume":"5","author":"Heirali","year":"2017","journal-title":"Microbiome"},{"key":"2022090715560877700_CIT0055","first-page":"thoraxjnl-2021-217782","article-title":"Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial","author":"Nichols","year":"2021","journal-title":"Thorax"},{"key":"2022090715560877700_CIT0056","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1513\/AnnalsATS.201211-107OC","article-title":"Changes in cystic fibrosis airway microbiota at pulmonary exacerbation","volume":"10","author":"Carmody","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"2022090715560877700_CIT0057","doi-asserted-by":"crossref","first-page":"e0194060","DOI":"10.1371\/journal.pone.0194060","article-title":"Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis","volume":"13","author":"Carmody","year":"2018","journal-title":"PLoS One"},{"key":"2022090715560877700_CIT0058","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jcf.2013.03.008","article-title":"Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis","volume":"12","author":"Reid","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0059","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1164\/rccm.200309-1306OC","article-title":"Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa","volume":"169","author":"Aaron","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090715560877700_CIT0060","first-page":"**","article-title":"Bacterial adaptation, diversification, and persistence in CF airways","volume":"**","author":"Planet","year":"2022","journal-title":"J Pediatr Infect Dis"},{"key":"2022090715560877700_CIT0061","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1183\/09031936.00202311","article-title":"Viral infections trigger exacerbations of cystic fibrosis in adults and children","volume":"40","author":"Wark","year":"2012","journal-title":"Eur Respir J"},{"key":"2022090715560877700_CIT0062","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1183\/13993003.01390-2015","article-title":"Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia","volume":"47","author":"Ratjen","year":"2016","journal-title":"Eur Respir J"},{"key":"2022090715560877700_CIT0063","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1164\/rccm.200306-779OC","article-title":"Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis","volume":"169","author":"Goss","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090715560877700_CIT0064","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/ppul.25250","article-title":"Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic","volume":"56","author":"Patel","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2022090715560877700_CIT0065","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2022090715560877700_CIT0066","article-title":"The impact of CFTR modulator therapies on CF airway microbiology","author":"Rogers","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0067","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2022090715560877700_CIT0068","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090715560877700_CIT0069","first-page":"CD002007","article-title":"Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis","volume":"12","author":"Elphick","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2022090715560877700_CIT0070","first-page":"CD002007","article-title":"Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis","volume":"6","author":"Holland","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2022090715560877700_CIT0071","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/cid\/ciab525","article-title":"Association between number of intravenous antipseudomonal antibiotics and clinical outcomes of pediatric cystic fibrosis pulmonary exacerbations","volume":"73","author":"Cogen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022090715560877700_CIT0072","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1513\/AnnalsATS.201702-111OC","article-title":"Treatment setting and outcomes of cystic fibrosis pulmonary exacerbations","volume":"15","author":"Schechter","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2022090715560877700_CIT0073","first-page":"S1569","article-title":"Antipseudomonal treatment decisions during CF exacerbation management","author":"VanDevanter","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0074","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jcf.2017.01.006","article-title":"The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis","volume":"16","author":"Garinis","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcf.2020.05.009","article-title":"Antimicrobial resistance: concerns of healthcare providers and people with CF","volume":"20","author":"Bullington","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0076","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1513\/AnnalsATS.201608-615OC","article-title":"Relationship of antibiotic treatment to recovery after acute FEV 1 decline in children with cystic fibrosis","volume":"14","author":"Morgan","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2022090715560877700_CIT0077","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"key":"2022090715560877700_CIT0078","first-page":"S1569","article-title":"Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation","author":"Sanders","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0079","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2020.07.008","article-title":"Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0080","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jcf.2016.04.009","article-title":"Episodic oral antibiotic use in CF: discordance between the electronic medical record and self-report","volume":"15","author":"Caverly","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0081","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2022090715560877700_CIT0082","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jcf.2020.02.012","article-title":"Finding the relevance of antimicrobial stewardship for cystic fibrosis","volume":"19","author":"Cogen","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2022090715560877700_CIT0083","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1513\/AnnalsATS.201401-034OI","article-title":"Is there a role for antimicrobial stewardship in cystic fibrosis?","volume":"11","author":"Waters","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"2022090715560877700_CIT0084","article-title":"Antimicrobial stewardship in CF","volume":"**:**-**","author":"Saiman","year":"2022","journal-title":"J Pediatr Infect Dis"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/11\/Supplement_2\/S40\/45741630\/piac062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/11\/Supplement_2\/S40\/45741630\/piac062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T16:03:03Z","timestamp":1662566583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/11\/Supplement_2\/S40\/6693711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":84,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2022,9,7]]},"published-print":{"date-parts":[[2022,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piac062","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,9,1]]}}}